
BioPlus Acquisition Corp.
BioPlus Acquisition Corp. (BIOS) Free Cash Flow & Analysis
Annual & trailing free cash flow, FCF margin, YoY change, valuation ratios, and peer context.
BIOS · free cash flow · updated Jun 9, 2026
Core FCF metrics
BIOS · FCF · TTM · margin & CAGRFree cash flow was −$691,465 for FY2022 (fiscal year ending 2022-12-31)
Annual free cash flow history
Annual free cash flow data
FCF valuation metrics
BIOS · P/FCF · FCF yield · FCF per shareBioPlus Acquisition Corp. (BIOS) reported negative free cash flow of −$0.00B. FCF-based valuation ratios are not meaningful when FCF is negative.
FCF-based valuation ratios are only meaningful when free cash flow is positive. Negative FCF indicates capital expenditures exceeded operating cash flow.
Cash flow statement summary
BIOS · cash flow statement · operating / investing / financingFor FY2022, BioPlus Acquisition Corp. generated −$0.7M in operating cash flow and spent 0M in capital expenditures, yielding −$0.7M in free cash flow.
For the complete Operating / Investing / Financing line-item breakdown:
View Full Cash Flow Statement →Free cash flow vs peers (Financial Services)
About Free Cash Flow & Methodology
BioPlus Acquisition Corp. (BIOS) reported free cash flow of −$691,465 for FY2022 (fiscal year ending 2022-12-31).
Based on available data, BioPlus Acquisition Corp. has maintained positive free cash flow for at least 3 fiscal year(s). FCF peaked at $26.5M in FY2011.
Data sourced from FMP /cash-flow-statement · SEC 10-K / 10-Q · USD.
Frequently asked questions
BIOS free cash flow · 8 questionsBioPlus Acquisition Corp. free cash flow was −$691,465 for FY2022. On a trailing twelve-month (TTM) basis, free cash flow stands at −$1.6M.
▸ Source: FMP /cash-flow-statement · US GAAP · BioPlus Acquisition Corp. · BioPlus Acquisition Corp. SEC 10-K & 10-Q filings · US GAAP · Last updated: Jun 9, 2026